The retatrutide black market: Patient safety groups warn of growing risks from understudied drugs
Past shortages of the blockbuster medications Ozempic, Mounjaro, Wegovy, and Zepbound triggered a surge in legitimately compounded, illegally compounded and black market GLP-1 sales. The supply gap normalized a trend of patients obtaining unapproved versions of these treatments, often from unlicensed sources. Now, as authorities struggle to stop the flow of imported, unapproved weight-loss medicines and contain illegal domestic compounding of GLP-1s, consumer attention has turned to a so-called “GLP-3,” the investigational drug retatrutide.
Online bodyhacking communities promote it, users speak in forums about using it, and some physicians are prescribing it to their patients even before it has gained FDA-approval. Despite the buzz, legitimate retatrutide is only available in Eli Lilly’s clinical trials, and consumers buying it from other sources cannot guarantee the identity or quality of what they receive. Australian physicians and British authorities report that patients have suffered side effects, liver failure and even death after taking the drug, but there is no regulated market for retatrutide; it's impossible to know what these patients injected, or what people are continuing to buy from online sellers, compounders and med spas.
Sponsored Google search results for retatrutide.
The unapproved retatrutide market holds immense safety risks for Americans and foreshadows a troubling future where bad actors routinely supply patients with inadequately researched substances from unknown suppliers despite the potential for terrible consequences.
Patient safety and consumer groups are urging regulators, law enforcement, and the healthcare community to act decisively to protect Americans by disrupting illegal supply chains, holding sellers accountable, and keeping unapproved and counterfeit products out of patients’ hands.
What safety groups are saying about the unregulated retatrutide market
Alliance for Safe Online Pharmacies (buysaferx.pharmacy)
“Retatrutide shows how fast an illicit market can form around a high-profile experimental drug. When an unapproved product is already widely available online, that's a warning sign — demand is outrunning legitimate access, and illegal sellers are stepping into the gap with products whose identity and quality can't be verified.”
– Dan Burke, Alliance for Safe Online Pharmacies (ASOP Global) Board Member & Former Division Chief, FDA Office of Criminal Investigations
Americans for Safe and Effective Medicines (safeandeffectivemeds.org)
“Retatrutide is not an FDA-approved drug, so consumers purchasing it on the black market have no way of knowing what's actually in it — no verified ingredients, no quality controls, no manufacturing oversight, and no accountability when something goes wrong. Patients deserve and want access to safe, effective treatment — not a system where bad actors exploit a lack of enforcement to sell whatever they want, however they want, with no one watching."
– Fred H. Mills, Jr., PharmD, Americans for Safe and Effective Medicines Chief Policy Officer, former Louisiana State Senator and former Executive Director of the Louisiana State Board of Pharmacy.
Collaborative for Evidence-Based Medicines (collaborativeebm.org)
“Promising isn't the same as proven. Excitement and consumer demand for a new therapy should not allow commercial availability to race ahead of the evidence needed to establish how a medicine can be used safely and effectively. Retatrutide is still being studied through controlled clinical trials, and illicit products sold outside that process bypass the scientific safeguards designed to ensure safety, effectiveness, and appropriate dosing. Patients deserve treatments supported by rigorous evidence—not unauthorized products marketed before the science is complete.”
– John Hertig, PharmD, Chair of the Board of Directors, Collaborative for Evidence-Based Medicines
National Consumers League (nclnet.org)
“Consumers should not mistake easy access for safety. Products marketed online or through wellness channels as retatrutide are being sold before the drug has even completed the FDA-approval process, often alongside misleading claims and ‘research use only’ labels that can obscure the serious risks of self-injecting an unapproved product. Consumers deserve clear, accurate information about what they are putting into their bodies, and they should not be put at risk by sellers trying to profit off of excitement around promising new weight-loss treatments.”
– Nancy Glick, National Consumers League Senior Director of Health Policy